Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · United Therapeutics (UTHR)

United Therapeutics adds Victor Dzau to its board, expanding it to 13 members

Neutral Impact 2 of 5 leadership Written later

United Therapeutics expanded its Board of Directors to 13 members and appointed Victor Dzau, M.D., effective July 22, 2026. Dr. Dzau will not initially serve on a board committee, and the company granted him director equity awards under its standard director compensation program.

Key points

  • Board size increased to 13 members; Dr. Dzau appointed July 22, 2026, with no initial committee assignment
  • Initial grant of 380 restricted stock units and 1,190 stock options, plus pro-rata grants of 350 RSUs and 1,110 options for the 2026-2027 board service year
  • Dr. Dzau previously served as President of the National Academy of Medicine for 12 years, with that term expiring in June 2026
  • Company describes the appointment as part of its ongoing board refreshment effort

The filing

CompanyUnited Therapeutics (UTHR)
Form8-K, current report
Filed with the SECJul 23, 2026, 7:00 AM ET
Accession number0001104659-26-086068

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:10 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 23, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.